Volume 7, supplement issue 1, June 2020

Real World Evidence for Oritavancin Use in Gram-Positive Infections

Issue editors

Matteo Bassetti
Teena Chopra

9 articles in this issue

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
- Content type: Announcement
- Open Access
- Published: 01 July 2020
- Pages: 1 - 1
Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes

Authors
- Mark Redell
- Content type: Commentary
- Open Access
- Published: 25 June 2020
- Pages: 2 - 5
The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies

Authors (first, second and last of 4)
- Sandy Estrada
- Thomas P. Lodise
- Dino Delaportas
- Content type: Original Research Article
- Open Access
- Published: 25 June 2020
- Pages: 6 - 12
Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience

Authors (first, second and last of 7)
- Lauren E. Brownell
- Meagan L. Adamsick
- Lucas T Schulz
- Content type: Original Research Article
- Open Access
- Published: 26 June 2020
- Pages: 13 - 19
Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis

Authors (first, second and last of 6)
- Brittany Helton
- Ashley MacWhinnie
- Steven L. Allison
- Content type: Original Research Article
- Open Access
- Published: 25 June 2020
- Pages: 20 - 29
Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway

Authors (first, second and last of 4)
- Cristen Whittaker
- Thomas P. Lodise
- Joseph Reilly
- Content type: Original Research Article
- Open Access
- Published: 25 June 2020
- Pages: 30 - 35
A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis

Authors
- Warren E. Rose
- Paul R. Hutson
- Content type: Original Research Article
- Open Access
- Published: 25 June 2020
- Pages: 36 - 40
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study

Authors (first, second and last of 8)
- Nicholas W. Van Hise
- Vishnu Chundi
- Russell M. Petrak
- Content type: Original Research Article
- Open Access
- Published: 25 June 2020
- Pages: 41 - 45
Real-World Use of Oritavancin for the Treatment of Osteomyelitis

Authors
- Patrick J. Scoble
- Joseph Reilly
- Glenn S. Tillotson
- Content type: Review Article
- Open Access
- Published: 25 June 2020
- Pages: 46 - 54

Volume 7, supplement issue 1, June 2020

Real World Evidence for Oritavancin Use in Gram-Positive Infections

Real-World Evidence for Oritavancin Use in Gram-Positive Infections

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies

Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study

Real-World Use of Oritavancin for the Treatment of Osteomyelitis

For authors

Explore

Volume 7, supplement issue 1, June 2020

Real World Evidence for Oritavancin Use in Gram-Positive Infections

Authors

Authors (first, second and last of 4)

Authors (first, second and last of 7)

Authors (first, second and last of 6)

Authors (first, second and last of 4)

Authors

Authors (first, second and last of 8)

Authors

For authors

Explore